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European Journal of Cardio-thoracic Surgery 34 (2008) 1—8AbstractAims: To critically review the available transcatheter aortic valve implantation techniques and their results, as well as propose recommenda-
tions for their use and development.Methods and results: A committee of experts including European Association of Cardio-Thoracic Surgery and
European Society of Cardiology representatives met to reach a consensus based on the analysis of the available data obtained with transcatheter
aortic valve implantation and their own experience. The evidence suggests that this technique is feasible and provides haemodynamic and clinical
improvement for up to 2 years in patients with severe symptomatic aortic stenosis at high risk or with contraindications for surgery. Questions
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A. Vahanian et al. / European Journal of Cardio-thoracic Surgery 34 (2008) 1—82candidates, perform the procedure, and assess the results. Today, the use of this technique should be restricted to high-risk patients or those with
contraindications for surgery. However, this may be extended to lower risk patients if the initial promise holds to be true after careful evaluation.
Conclusion: Transcatheter aortic valve implantation is a promising technique, which may offer an alternative to conventional surgery for high-
risk patients with aortic stenosis. Today, careful evaluation is needed to avoid the risk of uncontrolled diffusion.
# 2008 The European Society of Cardiology, European Association for Cardio-Thoracic Surgery, and Europa Edition. All rights reserved.
Keywords: Aortic stenosis; Valve disease; Percutaneous valve interventions1. Preamble
Valve disease is an important public health problem, as it
carries a poor prognosis and its prevalence is strongly linked
to the phenomenon of population ageing [1]. The most
frequent native valve disease in Europe is currently aortic
stenosis (AS), which is most often seen in elderly patients
with comorbidities [2]. Valve replacement is the definitive
therapy for patients with severe AS who have symptoms or
objective consequences such as left ventricular (LV) dysfunc-
tion [3,4]. Operative mortality is quite low, even in elderly
patients when properly selected, and long-term results have
been shown to be satisfactory [5,6]. However, the risk of
surgery may be higher in elderly patients with significant
comorbidities. In addition, several registries show that
referring physicians often do not propose surgery, as was
the case in the Euro Heart Survey with 33% of patients with
severe valve disease and severe symptoms not being
considered for surgery [7]. Thus, despite the good results
of valve surgery, there may well be a role for less invasive
alternatives.
Balloon aortic valvuloplasty (BAV) is now rarely used,
mainly due to its limited long-term efficacy [2].
Six years after the first-in-man [8], transcatheter aortic
valve implantation (TAVI) for the treatment of AS currently
represents a dynamic field of research and development: two
devices have been CE-marked and are being commercialized.
At this point in time, it is important for professional
societies to critically review the available TAVI techniques
and their results, as well as propose recommendations for
their use, development in clinical practice, and further
research [9,10]. On the 18—19th of November 2007, a
committee of experts, including EACTS and ESC representa-
tives, met. The consensus reached is summarized in the
current document, which was approved first by the
committee members and subsequently by the board of both
professional societies involved.
The Committee acknowledges that the conclusions in this
document rely on limited data reported mostly in oral
communications and few in peer-reviewed journals and are
temporally limited by the very nature of the document.2. Current techniques and results
Two devices are under clinical investigation for TAVI. One
device is the Edwards—Sapien valve (Edwards Lifesciences
Inc., CA, USA), which consists of three pericardial leaflets,
initially equine and currently bovine, mounted within a
tubular, slotted, stainless steel, balloon-expandable stent. It
is currently available in 23 and 26 mm sizes, necessitating,for the transfemoral approach, respectively, 22 and 24F
introducer sheaths, and for the transapical approach, this
measurement was 33F and is now 26F. The other device is the
CoreValve Revalving System (CRS TM, CoreValve Inc., Irvine,
CA, USA), which has three pericardial leaflets, initially bovine
and currently porcine, mounted in a self-expanding, nitinol
frame. It is available in 26 and 29 mm sizes, which go through
an18F introducer for transfemoral use, or very recently 21F for
the transapical route. (NB: the measurements of prosthesis
size quoted by the manufacturers do not correspond exactly
to those of surgically implanted prostheses.)
2.1. Techniques of implantation
TAVI is currently carried out using two different
approaches (retrograde transfemoral and anterograde trans-
apical), which share the same main principles. Most teams perform the procedure under general anaes-
thesia, although sedation and analgesia may suffice for the
transfemoral approach. Peri-procedural transoesophageal echocardiography (TEE)
monitoring is desirable to correctly position the valve as
well as to detect complications. After crossing the aortic valve, BAV is performed to pre-
dilate the native valve and serve as a rehearsal for TAVI.
Simultaneous rapid pacing decreases cardiac output,
stabilizing the balloon during inflation. Normal blood
pressure must be completely recovered between
sequences of rapid pacing. The following imaging methods can be used to position the
prosthesis at the aortic valve:
 Fluoroscopy to assess the level of valve calcification.
 Aortography, using different views, performed at the
beginning of the procedure and eventually repeated
with the undeployed prosthesis in place, to determine
the position of the valve and the plane of alignment of
the aortic cusps.
 Echocardiography: TEE is helpful, in particular, in cases
with moderate calcification. The additional value of
three-dimensional real-time TEE is currently being
evaluated. According to the limited current experience
with intracardiac echography, it does not seem to add to
TEE in this setting.When positioning is considered correct, the prosthesis is
released. Rapid pacing is used at this stage in balloon
expandable but not in self-expanding devices. Immediately after TAVI, aortography and, whenever
available, TEE or, in the absence of TEE, eventually
Transthoracic echo-cardiogram (TTE) are performed to
assess the location and degree of aortic regurgitation and
the patency of the coronary arteries and to rule out
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dissection. The haemodynamic results are assessed using
pressure recordings and/or echocardiography. After the procedure, the patients should stay in intensive
care for at least 24 h and be closely monitored for several
days especially as regards haemodynamics, vascular
access, rhythm disturbances (especially late atrioventri-
cular block), and renal function.
The following are the specific issues related to the
different approaches.
In the transfemoral approach, close attention should be
paid to the vascular access.
The common femoral artery can be either prepared
surgically or approached percutaneously. Echo-guided
femoral access could be useful. Manipulation of the
introductory sheaths should be careful and fluoroscopically
guided. Depending on the size of the device, closure of the
vascular access can be effected surgically or using a
percutaneous closure device [11].
For the transapical approach, femoral access and
cardiopulmonary bypass should be on standby in patients
in whom surgical conversion is an option in case of
complications. The technique requires an antero-lateral
mini-thoracotomy, pericardiotomy, identification of the
apex, and then puncture of the left ventricle using a needle
through purse-string sutures. Subsequently, an introductory
sheath is positioned in the LV, and the prosthesis is implanted
using the anterograde route.
2.2. Results
Since the first-in-man TAVI by Alain Cribier in 2002, well
over 1000 high-risk patients with severe symptomatic AS have
been treated using TAVI (as of January 2008).
2.2.1. Transfemoral approach
Over 400 cases have been performed using the balloon-
expandable and another 500 using the self-expandable
prosthesis (Company sources January 2008). Reports origi-
nate from a limited number of centres worldwide [12—17].
The patients treated were mostly >80 years old, at high risk
(e.g. Logistic EuroScore >20% in most cases), or with
contraindications for surgery.
The overall results can be summarized as follows:
Procedural success is closely linked to experience and is
90% in experienced centres. A learning curve can also be
observed resulting in better patient selection and outcomes.
Valve function is good with a final valve area ranging from 1.5
to 1.8 cm2.
Mortality at 30 days ranges from 5% to 18%. Acute
myocardial infarction occurs in 2—11%. Coronary obstruc-
tion is rare (<1%). Mild-to-moderate aortic regurgitation,
mostly paravalvular, is observed in 50% of cases.
However, the availability of larger prostheses and their
more careful matching with the size of the aortic
annulus led to the decrease in the incidence of severe
aortic regurgitation to 5%. Prosthesis embolisation is
rare, 1%.Vascular complications, with an incidence ranging from
10% to 15%, remain a significant cause of mortality and
morbidity. Stroke ranges from 3% to 9%. Finally, atrioven-
tricular block occurs in 4—8%, necessitating pacemaker
implantation in up to 24% with self-expandable devices.
Long-term results up to 2 years (though only 1 year in most
studies) are reported in a limited number of patients. They
show a survival rate of 70—80% with a significant improve-
ment in clinical condition in most cases. The majority of late
deaths are due to comorbidities.
Serial echocardiographic studies have consistently shown
good prosthetic valve function with no structural deteriora-
tion of valve tissue.
2.2.2. Transapical approach
The total experience with transapical aortic valve
implantation comprises over 300 patients, also at high risk
for conventional surgery, even more so because of con-
comitant peripheral arterial disease in most cases. Experi-
ence currently reported only relates to the balloon-
expandable prosthesis [18—21], although, the first-in-man
has been recently performed with the self-expandable
device.
The implantation success rate of the transapical proce-
dure is90%. Over 70% of cases are done off pump, the figure
being 90% in experienced centres, and the rate of peri-
operative conversion is 9—12%. Mortality rates range from 9%
to 18%. The incidence-of stroke is 0—6%. The quality of the
results seems closely related to experience as well as the
availability of high-quality imaging in the operating theatre
[19].
There are currently no direct comparative studies
available for the two approaches.
2.3. Perspectives
Progress in delivery systems and valve manufacturing
could lead to lower profile, repositionable, retrievable, and
more durable devices, as well as a wider range of prosthetic
valve dimensions. Furthermore, improved imaging, such as
online three-dimensional reconstruction and stereotaxis,
could facilitate valve placement.
2.4. Pending questions
In the light of the current experience, bearing in mind the
previously mentioned, inherent limitations of any conclu-
sions, TAVI using both balloon- and self-expandable devices
can be said to be feasible. Short- and mid-term haemody-
namic results are good up to 2 years. However, the technique
remains challenging, in particular, as regards vascular access,
device sizing, and positioning. The major concerns as regards
to safety are as follows: Vascular complications with the transfemoral approach,
which should decrease with smaller devices. Stroke rate, in particular, when using the transfemoral
approach. Long-term consequences of paravalvular leaks, even if
mild-to-moderate regurgitation is considered not to have
significant clinical consequences in the short-term.
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dictors of which have to be identified more precisely.
Mid (short)-term clinical outcome is encouraging, how-
ever, long-term durability of these bioprostheses and the
incidence of endocarditis or thrombo-embolic events remain
key questions, especially if considering lowering the thresh-
old for indication.
The feasibility of subsequent aortic valve intervention is
not known.3. Recommendations for the development of
transcatheter aortic valve implantation
3.1. Patient selection
Selection of candidates for TAVI, especially risk assess-
ment, should involve multi-disciplinary consultation
between cardiologists, surgeons, imaging specialists, anaes-
thesiologists, and possibly other specialists if necessary.
TAVI is indicated in patients with calcified pure or
predominant AS. It is unlikely that it will be used in patients
with pure aortic regurgitation.
Degeneration of an implanted aortic bioprosthesis (valve-
in-valve implantation) is an attractive potential indication
because of the high risk of re-operation in elderly patients.
However, the current experience is too limited to make any
recommendations.
The following are the four steps of patient selection: confirmation the severity of AS;
 evaluation of symptoms;
 analysis of the risk of surgery and evaluation of life
expectancy and quality of life; and
 assessment of the feasibility and exclusion of contra-
indications for TAVI.
3.1.1. Confirmation of the severity of aortic stenosis
TAVI should be performed only in severe AS. Echocardio-
graphy is the preferred tool to assess the severity of AS
according to a combination of measurements of valve area
and flow-dependent indices. Low-dose dobutamine echocar-
diography is useful to differentiate between severe and the
rare ‘pseudo severe’ AS in patients with low LV ejection
fraction and low gradient [3,4].
3.1.2. Evaluation of symptoms
At the present stage, TAVI should only be proposed in
patients with severe symptoms that can definitely be
attributed to valve disease because of pending questions
on safety and valve durability.
3.1.3. Analysis of the risks of surgery, and evaluation of
life expectancy and quality of life
Decision-making is particularly complex in these elderly
patients who represent a heterogeneous population and
require balanced and individualized analysis.
The evaluation of the risk of surgery is based on the
assessment of cardiac and extra cardiac factors [22]. Risk
scores, such as the EuroScore [23], the STS predicted risk ofmortality score [24], or the Ambler score [25], are of interest.
However, they all share similar limitations: predictive ability
is reduced in these high-risk patients who represent only a
small proportion of the population from which the scores
were elaborated; and high-risk patients form a particularly
heterogeneous group in which it is difficult to capture all the
comorbidities. The value of individual scores in this high-risk
population has yet to be specifically established [26]. The
predictive value of these scores for morbidity and long-term
results is also unknown.
TAVI should currently be restricted to patients at high-
risk or with contraindications for surgery. It is premature
to consider using it in patients who are good surgical
candidates.
For the Committee, the key element to establish
whether patients are at high risk for surgery is clinical
judgement, which should be used in association with a more
quantitative assessment, based on the combination of
several scores (for example expected mortality >20% with
the Logistic EuroScore and >10% with STS score). This
approach allows the team to take into account risk factors
that are not covered in scores but often seen in practice
such as chest radiation, previous aorto-coronary bypass with
patent grafts, porcelain aorta, liver cirrhosis, etc. Surgical
risk estimation should also bear in mind results in the given
institution [27].
At this stage, TAVI is not recommended for patients who
simply refuse surgery on the basis of personal preference.
Life expectancy is most significantly influenced by
comorbidities, which should be carefully looked for. In
addition to clinical evaluation, semi-quantitative scoring
systems, such as those used in geriatrics, may be helpful
[28]. Today, TAVI is seldom considered in patients <70,
however, age alone is not sufficient for its use instead
of surgery. TAVI should not be performed in patients
whose life expectancy is <1 year, who should be managed
conservatively.
3.1.4. Assessment of feasibility and exclusion of
contraindications of transcatheter aortic valve
implantation
The following steps should be taken to assess the
feasibility of TAVI.
3.1.4.1. Assessment of the coronary anatomy. Coronary
angiography should be performed to this end. If associated
coronary artery disease requires revascularization, whether
to proceed surgically, percutaneously, or in a hybrid manner,
as well as the chronology of interventions, should be the
subject of individualized discussion based on the patient’s
clinical condition and anatomy. TAVI is probably not
recommended in patients with severe proximal coronary
stenoses not amenable to percutaneous coronary interven-
tions.
The position of the coronary arteries relative to the aortic
cusps can be assessed using aortography or multislice
computed tomography [29].
3.1.4.2. Measurement of the aortic annulus. Correct sizing
of the valve is critical to minimize the potential for
paravalvular leakage and to avoid prosthesis migration
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measurement has yet to be established. TEE has been
found to show larger values than transthoracic echocardio-
graphy, thus, it should be performed if borderline values
lead to doubt the feasibility of the procedure [30].
Multislice computed tomography [29] or magnetic reso-
nance imaging could also be used for this purpose. Finally,
aortography measurements performed during BAV are also
useful.
Echocardiography is the preferred tool for the assessment
of the morphology of the LV outflow tract and, before
implanting self-expandable devices, the dimensions of the
aortic root.
3.1.4.3. Evaluation of size, tortuosity, and calcification of
peripheral arteries. Angiography is the reference; however,
multislice computed tomography can also be used. Finally,
magnetic resonance imaging is helpful in patients with renal
insufficiency.
Some contraindications are general, whereas others are
approach- or device-specific.
General contraindications for TAVI are as follows: Aortic annulus<18 or>25 mm for balloon-expandable and
<20 or >27 for self-expandable devices. Bicuspid valves because of the risk of incomplete
deployment of the prosthesis [31]. Presence of asymmetric heavy valvular calcification, which
may compress the coronary arteries during TAVI [15]. The
bulk and distribution of calcification in the valve may be
assessed by fluoroscopy and multislice computed tomo-
graphy. Finally, the risk of coronary compression can be
anticipated during BAV. Aortic root dimension >45 mm at the aorto-tubular
junction for self-expandable prostheses. Presence of apical LV thrombus.
The specific indications for transfemoral and transapical
approaches are not fully established and should be discussed
according to patient condition and local expertise.
Contraindications of the transfemoral approach are as
follows: Iliac arteries: severe calcification, tortuosity, small
diameter (<6—9 mm according to the device used),
previous aorto-femoral bypass. Aorta: severe angulation, severe atheroma of the arch,
coarctation, aneurysm of the abdominal aorta with
protruding mural thrombus. Presence of bulky atherosclerosis of the ascending aorta
and arch detected by TEE. Transverse ascending aorta (balloon-expandable device).
Contraindications for the transapical approach are as
follows: previous surgery of the LV using a patch, such as the Dor
procedure; calcified pericardium;
 severe respiratory insufficiency; and
 non-reachable LV apex.3.2. Performance of transcatheter aortic valve
implantation
The performance of TAVI, even more so ab initio, should
be restricted to a limited number of high-volume centres,
which have both cardiology and cardiac surgery departments,
with expertise in structural heart disease intervention and
high-risk valvular surgery.
The procedure requires the close cooperation of a team of
specialists in valve disease, including clinical cardiologists,
echocardiographists, interventional cardiologists, cardiac
surgeons, and anaesthesiologists.
Interventional cardiologists should be experienced in
catheter-based valvular interventions, and peripheral access
using large devices.
Cardiac surgeons should be experienced in valve surgery
and the management of complex cases.
The final organization may vary from centre to centre and
according to the type of procedure.
A multidisciplinary team approach and cross-fertilization
will be fundamental in the development of these procedures.
Because of the severe clinical condition of these patients,
the presence of anaesthesiologists with specific expertise in
cardiology is mandatory for peri- and post-operative care in
collaboration with cardiologists and cardiovascular surgeons.
A close collaboration with surgeons skilled in vascular
access repair and endo-vascular procedures is recommended
for transfemoral aortic valve implantation.
The aim of TAVI training is to acquire basic, then
advanced, and finally device-specific skills. It will concen-
trate on knowledge of valve disease (clinical assessment,
catheterization techniques, imaging), working in a sterile
environment, access management, understanding the equip-
ment, and anticipation and treatment of complications.
Training will be through didactic sessions, bench and/or
computer simulators, animal laboratories, hands-on training,
participation in established workshops, and proctoring during
the first cases.
The field of teaching and certification needs to be
significantly developed. A new subspecialization may be
necessary with a common training pathway for cardiologists
and surgeons wishing to practice TAVI.
At this early stage, data are insufficient to define a
minimum number of procedures required for competency.
Furthermore, individual experience must be continued in
order to conserve skills.
As regards the logistics, it is agreed that the operating
room and the catheterization laboratory should be as close
as possible to guarantee optimum patient safety. The
optimal environment for TAVI should be spacious and sterile,
and feature high-quality imaging equipment, and haemo-
dynamic monitoring and recording capabilities. However,
where to find such an environment is still under debate, as
both current surgical and interventional suites are sub-
optimal. Catheterization laboratories have good quality
imaging but may not be sterile and may induce delay in
rescue surgery. The opposite is often the case for operating
rooms.
A hybrid suite is ideal as it fulfils the role of both an
operating room and a catheterization laboratory. However,
most institutions do not have a hybrid room available, thus,
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one, which is highly desirable, cannot be overlooked.
It is the role of professional organizations such as the
EACTS and the ESC and their national equivalents to set
the standards for performance of the procedure and train-
ing and accreditation on an individual and institutional
level.
3.3. Evaluation of the results
Evaluation of the results of TAVI will present a significant
challenge because of the unique characteristics of this
patient population. Thus, comparison with current outcome
standards may not be appropriate. Close collaboration
between investigators, regulators, and the industry should
be assured early on.
The evaluation of new devices or techniques should be
performed in accordance with the stipulations of the
regulating authorities [32,33]. In Europe, TAVI devices are
classified in the highest risk group (class 3) as regards the
requirements for the putting of new devices on the market
[32]. Evaluation should adhere to the following pattern:
bench testing, in vitro, and animal implantation studies
(including bio-compatibility studies), then, only when
sufficient data are available, clinical investigation.
Clinical investigation should begin with the proof of
concept feasibility studies, followed by prospective clinical
investigations to determine safety and performance [34].
Randomized trials are themost rigorous design to evaluate
safety and efficacy in relation to other treatment modalities.
However, this is difficult with TAVI in relation to the most
high-risk patients, many of whom are currently not operated
on mostly due to non-referral [7]. Furthermore, the
contemporary natural history of unoperated patients is
incompletely known.
The Committee believes that randomized trials are highly
desirable once greater experience has been acquired, and
only small modifications in the technology used are to be
expected. The necessary clear definition of entry criteria for
these trials may be hindered by the inadequacy of risk scores
in these high-risk patients (see Section 3.1.3 for more
details).
In high-risk operable patients, TAVI should be compared
with valve replacement, in particular with the perspective of
patients who are in better clinical condition in the future. In
these patients, efficacy could be tested as non-inferiority vs
surgery, avoiding a too large delta, whereas safety can be
tested as superiority to surgery. In non-operable patients,
TAVI can be compared with the best available medical
treatment using the superiority design for efficacy; however,
this is more debatable and probably more difficult to run. A
randomized trial, PARTNER US, is currently ongoing where
the primary endpoint is all-cause mortality at 1 year. In the
future, the extension of TAVI to a lower risk patient
population should occur only in the setting of a randomized
trial.
As well as enrolment in randomized controlled trials, data
should be accumulated in registries. Such registries, which
may be regional, national, or international, are mandatory in
the evaluation of TAVI before its release in the general
medical community. Completeness of the data is essentialhere. The duration of follow-up to assess safety should be at
least 1 year in the pre-market phase and ideally 5 years for
post-marketing surveillance. Retrieval studies should also be
carried out if appropriate.
Irrespective of the study design, safety and efficacy
endpoints must be carefully defined.
Analysis will include the standard major adverse cardiac
events: mortality (30 day, in hospital, 1 year), stroke,
myocardial infarction, re-hospitalization, reoperation,
arrhythmias, and conduction disturbances. All adverse
events, anticipated and non-anticipated, should also be
reported to the health authority. Quality of life is paramount,
in particular, in these populations; thus, improvement should
be recorded using quality of life metrics, which should be
combined with cost effectiveness parameters. Endpoints
assessing valve function should follow the guidelines devel-
oped for valve surgery and include structural and non-
structural valve dysfunction, endocarditis, thrombo-embolism
and bleeding events.
Secondary endpoints, particular to TAVI, should also
include valve area and transvalvular gradient measurement,
paravalvular leaks, device migration, emergency valve-in-
valve implantation, conversion to conventional surgery, and
vascular complications.
These trials should be performed according to the
standards for clinical trials, i.e. central data collection
and analysis, data and safety monitoring board, core
laboratory analysis, and auditing and quality control, all
respecting the rules of independence from sponsors.
TAVI should currently be performed only in clinical studies
or as part of post-marketing registries. Clinical trials should
be limited to centres with experience in TAVI and trials, and
which actively participate in internal evaluation.
In centres performing TAVI, multi-disciplinary meetings
should be held on a regular basis to discuss indications,
procedural techniques, and case outcomes. Hospitals should
keep proof of close medico-surgical collaboration and
maintain a log of all patients referred for TAVI, regardless
of final treatment strategy, for continuous evaluation of the
programme [35]. Furthermore, a series of thorough quality
assurance measures should be included.4. Conclusion
The currently available results obtained with TAVI suggest
that these techniques are feasible and provide haemody-
namic and clinical improvement for up to 2 years in patients
with severe symptomatic AS at high risk or with contra-
indications for surgery. Pending questions concern mainly
safety and long-term durability. Surgeons and cardiologists
must work as a team to select the best candidates, perform
the procedure, and, finally, evaluate the results. Today, these
techniques are targeted at high-risk patients but they may be
extended to the lower risk group in the future, if the initial
promise holds true after careful evaluation. We are currently
at the stage of evaluation, and a careful commercialization
process including training and post-market surveillance is
crucial to avoid the risk of uncontrolled diffusion, which is
wholly undesirable at this stage of evolution of these
techniques.
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